Columbia University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Columbia University sits in the top decile of US sponsors by registered trial count (#34 of 15,742 sponsors by registered trial count).
Columbia University: 958 sponsored US clinical trials, 171 recruiting.
Columbia University sponsors 958 registered US clinical trials on ClinicalTrials.gov, 171 of them currently recruiting, and 597 completed. 88 of these trials are in Phase 3-4 (later-stage) and 191 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 9 trials.
Top-decile sponsor footprint
Columbia University ranks in the top decile of sponsors by registered trial count (#34 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
597 of 736 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
958 total, page 19 of 20
Study of Carotid Occlusion and Neurocognition
NCT00390481
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
NCT00365768
Enterra Therapy Gastric Stimulation System
NCT00556166
Incisional Hernia Outcomes Study Using Parietex Composite Mesh
NCT00459602
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)
NCT00104585
Documenting a Learning Curve and Test-retest Reliability of a Virtual Reality Training Simulator in Laparoscopic Surgery
NCT00435630
Nicotine as an Adjuvant Analgesic for Third Molar Surgery
NCT00385216
Study of CellCept for Advanced Pancreatic Cancer
NCT00997958
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
NCT00859469
Metabolic Effects of Differential Organ Growth Rates
NCT03219229
Effect of Nicotine on Chronic Pelvic Pain
NCT00440505
Usefulness of Integrative Medicine Tools As Adjunctive Care for Women After Coronary Artery Bypass Grafting
NCT01020227
Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities
NCT00629993
Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
NCT01611571
Adjuvant Oxytocin for Preinduction Ripening With a Foley catheter--a Clinical Trial
NCT00468520
Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)
NCT00385541
Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness
NCT01129583
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
NCT00670410
Intravenous Versus Inhalational Anesthesia in Parkinson's Disease
NCT00615472
Neurological Outcome With Carotid Artery Stenting
NCT00597974
A Prospective Study of Outcome After Therapy for Acromegaly
NCT01809808
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
NCT00801879
Anesthesia and Postoperative Pain
NCT00232817
Autologous and Allogeneic Transplant for Relapsed Lymphoma
NCT00802113
Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)
NCT00996333
Dissemination of Colorectal Cancer Screening to Primary Care Physicians
NCT00441311
Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia
NCT00208091
Prospective Study of Hormone Levels After Bariatric Surgery
NCT00627315
Neuropsychometric Outcome After Carotid Endarterectomy
NCT00597883
Prognostic Significance of T Wave Alternans
NCT00006501
Reduced Intensity AlloSCT in(CML) With Persistent Disease
NCT00531310
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
NCT01050439
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
NCT00041938
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
NCT01020539
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
NCT01019876
Leptin in Human Energy and Neuroendocrine Homeostasis
NCT00265980
Motivational Interviewing
NCT00208104
Effect of Cabergoline on Weight and Glucose Tolerance
NCT01395602
Asthma Self-Management For Adolescents
NCT01069991
Depression and Health Outcomes in Refractory Epilepsy
NCT00026637
Columbia Shoulder Study (CSS)
NCT01488006
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
NCT00027911
Randomized Trial of Telemedicine for Diabetes Care
NCT00271739
Effects of Desflurane and Propofol During Lung Volume Reduction Surgery
NCT04226625
Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis
NCT00004406
Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer
NCT00003851
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)
NCT00000607
Osteoporosis Prevention After Heart Transplant
NCT00000412
The Healthy Life Choices Project in HIV-Positive Patients
NCT00017810
Diabetes, Lipoproteins and Accelerated Vascular Disease
NCT00005479
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 105 |
| Phase 3 | 23 |
| Phase 4 | 65 |
Therapeutic Areas
What is open in the Columbia University pipeline
171 recruiting of 958 indexed (18% open); 597 completed (62%).
Phase mix: 88 late (III/IV) vs 191 early (I/II) (early-phase heavy).
Top condition: Obesity (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Columbia University: open-pipeline peers nationwide
Peers matched on 958 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Columbia University sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 958 trials (± recruiting share)
- University of Minnesota · 966 trials · 19% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- University of California, Los Angeles · 897 trials · 18% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Kite, A Gilead Company · 18% recruiting · 28 trials
- Mirum Pharmaceuticals · 18% recruiting · 28 trials
- West Virginia University · 18% recruiting · 122 trials
- Hospital for Special Surgery, New York · 18% recruiting · 194 trials
Related
What to do with this Columbia University page
958 registered trials is a research-attention snapshot, not an endorsement of Columbia University or any single study.
- 171 of Columbia University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Columbia University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Columbia University pipeline card: 958 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.